Skip Ribbon Commands
Skip to main content
Sign In
Unconventional ThinkingThe Otsuka WayMagnet

Unconventional Thinking

Our people aren’t afraid to challenge convention. This approach can lead to something new, something better.

Learn More

The Otsuka Way

We encourage our employees to dream.
Then we give them the freedom to reach for those dreams.

Magnet

​We aspire to attract best-in-class people and partners. After all, having the right team makes all the difference.

 

 About Otsuka

 

At Otsuka, we dream and act like a big venture company.

For us it all begins with a dream—a dream to help improve the lives of patients and their caregivers. Since our beginnings in 1921, we have been nurturing the spirit of curiosity, creativity, and perseverance in our employees so they may be inspired to pursue their dreams to bring innovative healthcare products to patients and communities worldwide.

Our people aren’t afraid to challenge convention. This is what defines big venture. We explore for ourselves rather than rely on the conclusions of others. Together we experiment, and sometimes challenge each other, in our collective passion to discover something new, something better. That is the energy that powers Otsuka.

In North America, Otsuka Pharmaceutical Co., Ltd. operates three pharmaceutical companies dedicated to creating and promoting new products and innovative solutions for better health worldwide, with a focus on four specialty areas: neuroscience, oncology, cardio-renal, and medical devices. Explore Otsuka and see what sets us apart.

 

 Latest News

 
April 26, 2016

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announced that the United States Food and Drug ...

April 18, 2016

Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization (Otsuka) commend the recent ...

February 08, 2016
  • ​The safety and efficacy of REXULTI (brexpiprazole) as maintenance treatment in adults with schizophrenia aged 18 to 65 years was dem...

Service Execution Profile

Service NameExecutedExecution Time (ms)
GetArticlesTrue15.625
Total Execution Time31.25

Service: GetArticles (Hps.Orchestration.Services.Moss.QueryWebListItems)

Input Parameters
Input NameSourceTypeValue
ListNameWebPartParameterstring/newsroom/Lists/NewsReleases
OutputTypeLiteralstringXML
ListColumnsLiteralstringID,Title,Attachments,Summary,AuthoredBy,AuthoredOn
CamlQueryLiteraltext<Where><And> <Or> <Leq> <FieldRef Name='PublishingStartDate'/> <Value Type='DateTime' IncludeTimeValue='TRUE'><Today/></Value> </Leq> <IsNull> <FieldRef Name='PublishingStartDate'/> </IsNull> </Or> <Or> <Geq> <FieldRef Name='PublishingExpirationDate'/> <Value Type='DateTime' IncludeTimeValue='TRUE'><Today/></Value> </Geq> <IsNull> <FieldRef Name='PublishingExpirationDate'/> </IsNull> </Or></And></Where><OrderBy><FieldRef Name="SortOrder" Ascending="True" /><FieldRef Name="AuthoredOn" Ascending="False" /></OrderBy>
RowLimitWebPartParameterstring3
page_urlSystemstringhttp://www.otsuka-us.com/Pages/default.aspx
item_startRequeststring1
page_sizeWebPartParameterstring10
TruncateSummaryWebPartParameterstringtrue
Output Parameters
NameScopeValue
page_urlRequesthttp://www.otsuka-us.com/Pages/default.aspx
item_startRequest1
page_sizeRequest10
TruncateSummaryRequesttrue
XmlOutputRequest<ListItems count="3" listName="News Releases" rootFolder="/newsroom/Lists/NewsReleases" listId="9390c4a8-f240-461a-abb7-de8da17f297f" displayForm="/newsroom/Lists/NewsReleases/DispForm.aspx" editForm="/newsroom/Lists/NewsReleases/EditForm.aspx" newForm="/newsroom/Lists/NewsReleases/NewForm.aspx"> <SystemInfo> <CurrentDate day="29" month="4" year="2016" dow="Friday">04/29/2016</CurrentDate> <CurrentTime hour="04" minute="01" second="19">04:01:19</CurrentTime> <Site id="ed6ad9ce-fe65-4df9-a713-7972717b701e" title="Home" url="http://www.otsuka-us.com" relativeUrl="/" /> <Web id="d83a7403-bff2-42fd-a8d2-baa10dc60756" title="News Room" url="http://www.otsuka-us.com/newsroom" relativeUrl="/newsroom" /> </SystemInfo> <ListItem id="23" randomId="433"> <ID type="Counter" name="ID">23</ID> <Title type="Text" name="Title">FDA Issues Complete Response Letter for Digital Medicine New Drug Application</Title> <Attachments type="Attachments" name="Attachments" count="0" /> <Summary type="Note" name="Summary"><![CDATA[<div class="ExternalClassF96EBD58D77240D29A7E54247D45DB2E"><p>​<span>Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for their Digital Medicine, a drug/device combination product, which combines Otsuka’s ABILIFY<sup>®</sup> (aripiprazole), an atypical antipsychotic, with the FDA-cleared Proteus ingestible sensor, embedded in a single tablet at point of manufacture.</span></p></div>]]></Summary> <AuthoredBy type="Text" name="Authored By"></AuthoredBy> <AuthoredOn type="DateTime" name="Authored On" day="26" month="4" year="2016" dow="Tuesday" hour="00" minute="00" second="00">4/26/2016 12:00:00 AM</AuthoredOn> </ListItem> <ListItem id="21" randomId="775"> <ID type="Counter" name="ID">21</ID> <Title type="Text" name="Title">Otsuka U.S. Pharmaceutical Affiliates Praise Establishment of Mental Health and Substance Use Disorder Parity Task Force</Title> <Attachments type="Attachments" name="Attachments" count="0" /> <Summary type="Note" name="Summary"><![CDATA[<div class="ExternalClass5FE2AD43B1D04F91A5D2AAEA5E4357AC"><div><p>​<span>Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development &amp; Commercialization (Otsuka) commend the recent announcement from President Obama that he will establish an inter-agency Mental Health and Substance Use Disorder Parity Task Force to better ensure compliance with and implementation of requirements related to mental health and substance use disorder parity.</span></p></div></div>]]></Summary> <AuthoredBy type="Text" name="Authored By"></AuthoredBy> <AuthoredOn type="DateTime" name="Authored On" day="18" month="4" year="2016" dow="Monday" hour="00" minute="00" second="00">4/18/2016 12:00:00 AM</AuthoredOn> </ListItem> <ListItem id="19" randomId="478"> <ID type="Counter" name="ID">19</ID> <Title type="Text" name="Title">U.S. FDA Accepts For Review Otsuka and Lundbeck’s sNDA Filing for Labeling Update of REXULTI&lt;sup&gt;®&lt;/sup&gt; (brexpiprazole) for Maintenance Treatment of Schizophrenia</Title> <Attachments type="Attachments" name="Attachments" count="0" /> <Summary type="Note" name="Summary"><![CDATA[<div class="ExternalClass37DFD4758F5C4EF38CD0744895ECBDD9"><ul><li>​The safety and efficacy of REXULTI (brexpiprazole) as maintenance treatment in adults with schizophrenia aged 18 to 65 years was demonstrated in a 52-week randomized withdrawal trial. </li> <li>The anticipated date for the FDA to complete its review of the proposed expanded labeling is [insert date]. REXULTI was approved by the U.S. FDA in July 2015 as a treatment for adults with schizophrenia and as an adjunctive treatment for adults with major depressive disorder. </li> <li>There are approximately 2.4 million adults in the U.S. with schizophrenia and around 75% of patients experience relapses where their symptoms come back or, in some cases, worsen.</li></ul></div>]]></Summary> <AuthoredBy type="Text" name="Authored By"></AuthoredBy> <AuthoredOn type="DateTime" name="Authored On" day="8" month="2" year="2016" dow="Monday" hour="00" minute="00" second="00">2/8/2016 12:00:00 AM</AuthoredOn> </ListItem> </ListItems>
TotalResultsRequest3
ReturnStatusRequesttrue

Final Output Parameters

NameScopeValue
ExecutionStatusRequesttrue
item_startRequest1
page_sizeRequest10
page_urlRequesthttp://www.otsuka-us.com/Pages/default.aspx
ReturnStatusRequesttrue
TotalResultsRequest3
TruncateSummaryRequesttrue
XmlOutputRequest<ListItems count="3" listName="News Releases" rootFolder="/newsroom/Lists/NewsReleases" listId="9390c4a8-f240-461a-abb7-de8da17f297f" displayForm="/newsroom/Lists/NewsReleases/DispForm.aspx" editForm="/newsroom/Lists/NewsReleases/EditForm.aspx" newForm="/newsroom/Lists/NewsReleases/NewForm.aspx"> <SystemInfo> <CurrentDate day="29" month="4" year="2016" dow="Friday">04/29/2016</CurrentDate> <CurrentTime hour="04" minute="01" second="19">04:01:19</CurrentTime> <Site id="ed6ad9ce-fe65-4df9-a713-7972717b701e" title="Home" url="http://www.otsuka-us.com" relativeUrl="/" /> <Web id="d83a7403-bff2-42fd-a8d2-baa10dc60756" title="News Room" url="http://www.otsuka-us.com/newsroom" relativeUrl="/newsroom" /> </SystemInfo> <ListItem id="23" randomId="433"> <ID type="Counter" name="ID">23</ID> <Title type="Text" name="Title">FDA Issues Complete Response Letter for Digital Medicine New Drug Application</Title> <Attachments type="Attachments" name="Attachments" count="0" /> <Summary type="Note" name="Summary"><![CDATA[<div class="ExternalClassF96EBD58D77240D29A7E54247D45DB2E"><p>​<span>Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for their Digital Medicine, a drug/device combination product, which combines Otsuka’s ABILIFY<sup>®</sup> (aripiprazole), an atypical antipsychotic, with the FDA-cleared Proteus ingestible sensor, embedded in a single tablet at point of manufacture.</span></p></div>]]></Summary> <AuthoredBy type="Text" name="Authored By"></AuthoredBy> <AuthoredOn type="DateTime" name="Authored On" day="26" month="4" year="2016" dow="Tuesday" hour="00" minute="00" second="00">4/26/2016 12:00:00 AM</AuthoredOn> </ListItem> <ListItem id="21" randomId="775"> <ID type="Counter" name="ID">21</ID> <Title type="Text" name="Title">Otsuka U.S. Pharmaceutical Affiliates Praise Establishment of Mental Health and Substance Use Disorder Parity Task Force</Title> <Attachments type="Attachments" name="Attachments" count="0" /> <Summary type="Note" name="Summary"><![CDATA[<div class="ExternalClass5FE2AD43B1D04F91A5D2AAEA5E4357AC"><div><p>​<span>Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development &amp; Commercialization (Otsuka) commend the recent announcement from President Obama that he will establish an inter-agency Mental Health and Substance Use Disorder Parity Task Force to better ensure compliance with and implementation of requirements related to mental health and substance use disorder parity.</span></p></div></div>]]></Summary> <AuthoredBy type="Text" name="Authored By"></AuthoredBy> <AuthoredOn type="DateTime" name="Authored On" day="18" month="4" year="2016" dow="Monday" hour="00" minute="00" second="00">4/18/2016 12:00:00 AM</AuthoredOn> </ListItem> <ListItem id="19" randomId="478"> <ID type="Counter" name="ID">19</ID> <Title type="Text" name="Title">U.S. FDA Accepts For Review Otsuka and Lundbeck’s sNDA Filing for Labeling Update of REXULTI&lt;sup&gt;®&lt;/sup&gt; (brexpiprazole) for Maintenance Treatment of Schizophrenia</Title> <Attachments type="Attachments" name="Attachments" count="0" /> <Summary type="Note" name="Summary"><![CDATA[<div class="ExternalClass37DFD4758F5C4EF38CD0744895ECBDD9"><ul><li>​The safety and efficacy of REXULTI (brexpiprazole) as maintenance treatment in adults with schizophrenia aged 18 to 65 years was demonstrated in a 52-week randomized withdrawal trial. </li> <li>The anticipated date for the FDA to complete its review of the proposed expanded labeling is [insert date]. REXULTI was approved by the U.S. FDA in July 2015 as a treatment for adults with schizophrenia and as an adjunctive treatment for adults with major depressive disorder. </li> <li>There are approximately 2.4 million adults in the U.S. with schizophrenia and around 75% of patients experience relapses where their symptoms come back or, in some cases, worsen.</li></ul></div>]]></Summary> <AuthoredBy type="Text" name="Authored By"></AuthoredBy> <AuthoredOn type="DateTime" name="Authored On" day="8" month="2" year="2016" dow="Monday" hour="00" minute="00" second="00">2/8/2016 12:00:00 AM</AuthoredOn> </ListItem> </ListItems>
 

 Corporate Video

 
July 2015    01US15EXC0017